Key points:
-
Oventus signs first material agreements with sleep medicine groups in Canada for its O2Vent® Sleep Treatment Platform which treats obstructive sleep apnoea (OSA)
-
The exclusive supply agreements are with two sleep groups in Canada which represent 7 clinical delivery sites
-
Oventus expects to secure further agreements across North America over the next 12- 24 month
-
Negotiations ongoing with multiple groups across Canada, the US and Australia with a view to significant scaling through the end of calendar 2019 and 2020
Brisbane, Australia 24 June 2019: Oventus Medical Ltd or the Company (ASX: OVN) is pleased to announce it has signed its first material contracts with Canadian sleep medicine groups who will adopt the Company’s O2Vent® Sleep Treatment Platform. The launch with the two groups, which represent 7 clinical delivery sites, is scheduled for July 2019.
For further information please download the attached PDF:
Download this document
